



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Alexander Vugler,
✉ alexander.vugler@ucb.com
James O'Connell,
✉ jimioconnell@virginmedia.com

[†]PRESENT ADDRESS
Peter Florian, Boehringer Ingelheim Vetmedica
GmbH, Global AH Research, Ingelheim am
Rhein, Germany

RECEIVED 12 August 2024
ACCEPTED 26 September 2024
PUBLISHED 16 October 2024

CITATION
Vugler A, O'Connell J, Nguyen MA, Weitz D,
Leeuw T, Hickford E, Verbitsky A, Ying X,
Rehberg M, Carrington B, Merriman M, Moss A,
Nicolas J-M, Stanley P, Wright S, Bourne T,
Foricher Y, Zhu Z, Brookings D, Horsley H,
Heer J, Schio L, Herrmann M, Rao S,
Kohlmann M and Florian P (2024) Corrigendum:
An orally available small molecule that targets
soluble TNF to deliver anti-TNF biologic-like
efficacy in rheumatoid arthritis.
Front. Pharmacol. 15:1479557.
doi: 10.3389/fphar.2024.1479557

COPYRIGHT
© 2024 Vugler, O'Connell, Nguyen, Weitz,
Leeuw, Hickford, Verbitsky, Ying, Rehberg,
Carrington, Merriman, Moss, Nicolas, Stanley,
Wright, Bourne, Foricher, Zhu, Brookings,
Horsley, Heer, Schio, Herrmann, Rao, Kohlmann
and Florian. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Alexander Vugler^{1*}, James O'Connell^{2*}, Mai Anh Nguyen³,
Dietmar Weitz⁴, Thomas Leeuw⁵, Elizabeth Hickford⁶,
Alexander Verbitsky⁷, Xiaoyou Ying⁷, Markus Rehberg⁸,
Bruce Carrington², Mark Merriman¹, Andrew Moss⁹,
Jean-Marie Nicolas¹⁰, Phil Stanley¹, Sara Wright¹¹, Tim Bourne¹²,
Yann Foricher¹³, Zhaoning Zhu¹⁴, Daniel Brookings¹⁴,
Helen Horsley¹⁴, Jag Heer¹⁴, Laurent Schio¹³,
Matthias Herrmann⁵, Srinivas Rao⁷, Markus Kohlmann¹⁵ and
Peter Florian^{5†}

¹Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom, ²Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom, ³Sanofi R&D, TMED Pharmacokinetics Dynamics and Metabolism, Frankfurt am Main, Germany, ⁴Sanofi R&D, Drug Metabolism and Pharmacokinetics, Frankfurt am Main, Germany, ⁵Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany, ⁶Development Science, PV Early Solutions, UCB Pharma, Slough, United Kingdom, ⁷Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States, ⁸Sanofi R&D, Translational Disease Modelling, Frankfurt am Main, Germany, ⁹Translational Medicine Immunology, PV Early Solutions, UCB Pharma, Slough, United Kingdom, ¹⁰Development Science, Drug Metabolism and Pharmacokinetics, UCB Pharma, Braine-l'Alleud, Belgium, ¹¹Early PV Missions, PV Early Solutions, UCB Pharma, Slough, United Kingdom, ¹²Milvuswood Consultancy, Penn, United Kingdom, ¹³Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France, ¹⁴Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom, ¹⁵Sanofi R&D, Early Clinical Development, Therapeutic Area Immunology and Inflammation, Frankfurt am Main, Germany

KEYWORDS

TNF, rheumatoid arthritis, small molecule, TNF trimer, immunogenicity

A Corrigendum on An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

by Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicholas J-M, Stanley P, Wright S, Bourne T, Foricher Y, Brookings D, Horsley H, Heer J, Laurent S, Herrmann M, Rao S, Kohlmann M and Florian P (2022). *Front. Pharmacol.* 13:1037983. doi: 10.3389/fphar.2022.1037983

In the published article, there was an error in **Affiliation 13**. Instead of “Sanofi R&D, Integrated Drug Discovery, Medicinal Chemistry, Therapeutic Area Immunology & Inflammation, Vitry-sur-Seine, France”, it should be “Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France”.

In the published article, there was an error in the **Author list**, and authors Zhaoning Zhu, Jag Heer, and Laurent Schio were erroneously excluded. The corrected author list appears below.

Alexander Vugler¹, James O'Connell^{2*}, Mai Anh Nguyen³, Dietmar Weitz⁴, Thomas Leeuw⁵, Elizabeth Hickford⁶, Alexander Verbitsky^{7*}, Xiaoyou Ying⁷, Markus Rehberg⁸, Bruce Carrington², Mark Merriman¹, Andrew Moss⁹, Jean-Marie Nicholas¹⁰, Phil Stanley¹, Sara Wright¹¹, Tim Bourne¹², Yann Foricher¹³, Zhaoning Zhu¹⁴, Daniel Brookings¹⁴, Helen Horsley¹⁴, Jag Heer¹⁴, Laurent Schio¹³, Matthias Herrmann⁵, Srinivas Rao⁷, Markus Kohlmann¹⁵ and Peter Florian^{5†}

In the published article, there was an error in the **Conflict of Interest** statement. The individual involvement of Zhaoning Zhu, Jag Heer, and Laurent Schio was omitted. The correct Conflict of Interest statement appears below.

In the published article, there was an error in the **Author contributions** statement. The individual contributions of Zhaoning Zhu, Jag Heer, and Laurent Schio were omitted. The correct Author contributions statement appears below.

Author contributions

MK, JO'C, AV, and PF wrote the first draft and compiled the final manuscript. The key data and overall concept of the manuscript was led by AV and PF who were the pharmacology leads on the oral TNF inhibitor program between UCB and Sanofi. In vitro assay data were summarized and provided by EH, BC, MM, and AM together with TL who finally reviewed the data. MN, DW, J-MN, and MR contributed with expert views on PKDM, DMPK and QSP modelling, respectively. The micro-CT study of the CIA model

samples was performed by AVe and XY. SR provided pathology view and expert input on some primary CT images. PS conducted the statistical analysis of the CIA in vivo model data and provided the graphical representation. ZZ, LS, DB, HH, JH, and YF were instrumental in the discovery and synthesis of the compound. ZZ and LS were the chemistry leads between UCB and Sanofi. SW, TB and MH were the global project leads for the oral TNF inhibitor program and revised the final version prior to submission.

Conflict of interest

AV, JO'C, MN, DW, TL, EH, AVe, XY, MR, BC, MM, AM, J-MN, PS, SW, YF, ZZ, DB, HH, JH, LS, MH, SR, MK, and PF are either employees of UCB Pharma or Sanofi and may hold stock of the respective organizations. PF was employed by Sanofi-Aventis Deutschland GmbH at the time the work of the manuscript was conducted. He is now an employee of Boehringer Ingelheim Vetmedica GmbH. TB was employed by Milvuswood Consultancy.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.